Pathology of serrated colorectal lesions

Adrian C Bateman

ABSTRACT
The concept of serrated colorectal neoplasia has become recognised as a key process in the development of colorectal cancer (CRC) and an important alternative pathway to malignancy compared with the long-established ‘adenoma-carcinoma’ sequence. Increasing recognition of the morphological spectrum of serrated lesions has occurred in parallel with elucidation of the distinct molecular genetic characteristics of progression from normal mucosa, via the ‘serrated pathway’, to CRC. Some of these lesions can be difficult to identify at colonoscopy. Challenges for pathologists include the requirement for accurate recognition of the forms of serrated lesions that are associated with a significant risk of malignant progression and therefore the need for widely disseminated reproducible criteria for their diagnosis. Alongside this process, pathologists and endoscopists need to formulate clear guidelines for the management of patients with these lesions, particularly with respect to the optimal follow-up intervals. This review provides practical guidance for the recognition of these lesions by pathologists, a discussion of ‘serrated adenocarcinoma’ and an insight into the distinct molecular genetic alterations that are seen in this spectrum of lesions in comparison to those that characterise the classic ‘adenoma-carcinoma’ sequence.

INTRODUCTION
Until relatively recently the only serrated (‘saw tooth’) colorectal lesion that many diagnostic histopathologists were aware of was the hyperplastic polyp. The term ‘serrated polyp’ was first used in 1990 by Longacre and Fernoglio-Preiser to describe a newly recognised form of colorectal polyp that showed features of a conventional adenoma and a hyperplastic polyp. This lesion subsequently became known as the ‘traditional’ serrated adenoma (TSA).1 Torlakovic and Snover later identified subtle differences between sporadically occurring hyperplastic polyps and the polyps found in the condition initially known as ‘hyperplastic polyposis’. These polyps showed a constellation of features that were distinct from both sporadic hyperplastic polyps and TSAs, and this led to the recognition of the ‘sessile serrated lesion’ (SSL).2 SSLs can of course occur sporadically as well as in the setting of polyposis. Jass later demonstrated that SSLs were associated with a distinct molecular pathway to colorectal cancer (CRC).3 Jass highlighted the biological importance of these ‘hyperplastic polyp-like’ lesions that were more commonly found within the right colon, were usually sessile and relatively large (often 10 mm or more in diameter) but that did not show features of dysplasia as seen in ‘classical’ adenomas.4

As a result of these and other studies, a spectrum of colorectal polyps exhibiting a partially or wholly serrated architecture is now recognised (table 1). Some of these lesions show no dysplasia of any recognised form while others show ‘dysmaturation’ that is now recognised by at least some pathologists as a subtle form of dysplasia. Finally, some serrated lesions show ‘conventional’ dysplasia, as is already widely recognised by histopathologists as an integral feature of ‘classical’ colorectal adenomas. These areas of ‘conventional’ dysplasia may be low grade or high grade in nature and in the setting of serrated colorectal polyps, and are usually present within one or more areas of the polyp, combined with other areas that do not show ‘conventional’ dysplasia. This heterogeneous appearance has led to use of the term ‘mixed polyp’ by some groups.

During the process of recognition of the serrated colorectal polyp ‘spectrum’, several names have been used to describe some of these lesions and this has led to terminological confusion. The key skill for the diagnostic histopathologist is the ability to recognise that some colorectal lesions that would probably previously have been called ‘hyperplastic polyps’, with the implication that they are not associated with a significant increase in CRC risk, may in fact represent one of the forms of colorectal polyp that can progress to malignancy.

The ability of histopathologists to differentiate accurately between types of serrated lesion is most pertinent during the differentiation between SSLs and hyperplastic polyps, as SSLs are the lesions that may not show conventional dysplasia, yet are associated with an increased risk of progression to CRC.

CRC arising in association with serrated polyps most often shows histological features that are not distinguishable from those of CRC arising in association with ‘classical’ adenomas. Alternatively, it may show a range of morphological appearances that are characteristic of ‘serrated adenocarcinoma’.5 The molecular alterations occurring during progression to CRC along the ‘serrated pathway’ are distinct to those occurring within the classical ‘adenoma-carcinoma sequence’, and there is evidence that this progression occurs more quickly within the ‘serrated pathway’.6

THE SPECTRUM OF SERRATED LESIONS

Hyperplastic polyp
Hyperplastic polyps are very commonly encountered by all pathologists who report colorectal lesions. They occur at all sites within the large intestine—although they are most common within the distal colon and rectum—and are classically less than 10 mm in size. They share some histological features with SSLs, for example, a serrated architecture. Three morphological variants exist—microvillous, goblet cell and mucin-poor (figure 1). Very few pathologists will use this subclassification
system for hyperplastic polyps in a routine setting. Despite this, knowledge of the spectrum of appearances of hyperplastic polyps may facilitate their positive identification and therefore facilitate their differentiation from other serrated lesions, especially SSLs (table 2).

Hyperplastic polyps have historically not been considered as precursor lesions to CRC. However, both BRAF and KRAS mutations (see later) are common in these lesions and are likely to be important steps in their development.8

**Sessile serrated lesions**

SSLs (also known as ‘sessile serrated polyps’ or ‘sessile serrated adenomas’) resemble hyperplastic polyps on initial examination. Indeed, differentiation between hyperplastic polyps and SSLs can be problematic, especially with small biopsies or those showing crush, diathermy or tangential cutting artefact. SSLs are most commonly encountered in the right colon,2 although they can occur throughout the large intestine. As their name suggests, they are usually sessile in nature (itself a difficult quality to define with absolute clarity). They may be over 10 mm in diameter, although interestingly, around one-third of SSLs are 5 mm or less across.2 The characteristic histological features of SSLs are listed in box 1 (figure 2). There is some difference of opinion regarding how many of these characteristic features are required and how widespread they need to be in order to make a diagnosis of SSL. For example, the American Gastroenterology Association Guidelines suggest that when assessing a serrated lesion, the presence of a single crypt

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Suggested prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperplastic polyp</td>
<td>25–30% of all colorectal polyps</td>
</tr>
<tr>
<td>10–20% of Western adults</td>
<td></td>
</tr>
<tr>
<td>Sessile serrated lesion (SSL)</td>
<td>1.7–9% of all colorectal polyps</td>
</tr>
<tr>
<td>SSL with ‘conventional’ dysplasia</td>
<td>13.2% of all SSLs</td>
</tr>
<tr>
<td>Traditional serrated adenoma</td>
<td>0.6–1.9% of all colorectal polyps</td>
</tr>
<tr>
<td>Serrated adenocarcinoma</td>
<td>9–12% of all colorectal adenocarcinomas</td>
</tr>
</tbody>
</table>

Figure 1  The histological features of hyperplastic polyps. (a) Microvesicular variant. Magnification ×100. (b) Microvesicular variant. Magnification ×200. (c) Base of crypts to show proliferative zone. Magnification ×200. (d) Mucin-poor variant. Magnification ×400. (e) Microvesicular variant. Magnification ×400. (f) Goblet cell variant. Magnification ×100. All—H&E stain.
showing one of the characteristic features is sufficient in order to
diagnose a SSL.9 In contrast, the World Health Organisation
criteria include a statement that at least three crypts—or two
adjacent crypts—must show the characteristic features for the
diagnosis to be reached.10 SSLs share some histological features
with the microvesicular variant of hyperplastic polyp, while
BRAF mutations are common within both lesions. These fea-
tures have led some to suggest that SSLs may evolve from hyper-
plastic polyps.8 If this is true and hyperplastic polyps are indeed
classical half of crypts. However, such
immunohistochemistry, while sometimes helpful, does not reveal
features that are alone diagnostic of SSL.

SSL, sessile serrated lesion.

<table>
<thead>
<tr>
<th>Variant</th>
<th>Clinical features</th>
<th>Histological features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microvesicular</td>
<td>Usually found in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>the distal colon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and rectum</td>
<td></td>
</tr>
<tr>
<td>Mucin poor</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Goblet cell</td>
<td>Distal colon and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rectum</td>
<td></td>
</tr>
</tbody>
</table>
| Dilatation of crypt bases
| Serration present at crypt bases
| Branching of crypt bases
| Horizontal extension of crypt bases†
| Dysmaturation of crypts†
| Hemiation of crypts through muscularis mucosa
| World Health Organisation criteria—at least three crypts or at
| least two adjacent crypts must show one or more of these
| features to enable a diagnosis of SSL10
| American Gastroenterology Association criteria—one crypt
| showing the characteristic features is sufficient for the diagnosis
| of SSL8

†Involved crypts often have an ‘L’ or inverted ‘T’ shape.

‡Dysmaturation is disordered cellular maturation within crypts
and is evidenced by subtle nuclear enlargement, crowding,
pseudostratification and mitotic activity together with
the presence of a disorganised mixture of non-mucus-containing
epithelial cells and mature goblet cells within the deep aspects
of crypts. In this context, assessment of proliferation index, for
example, using MIB-1 may provide supporting evidence for a
diagnosis of SSL by highlighting epithelial cell proliferation
within the superficial half of crypts. However, such
immunohistochemistry, while sometimes helpful, does not reveal
features that are alone diagnostic of SSL.

Box 1 Key histological features of SSLs2 5

Irregular distribution of crypts
Dilatation of crypt bases
Serration present at crypt bases
Branching of crypts
Horizontal extension of crypt bases†
Dysmaturation of crypts†
Hemiation of crypts through muscularis mucosa
World Health Organisation criteria—at least three crypts or at
least two adjacent crypts must show one or more of these
features to enable a diagnosis of SSL10
American Gastroenterology Association criteria—one crypt
showing the characteristic features is sufficient for the diagnosis
of SSL8

There is evidence that the reproducibility of diagnosis of SSLs
is poor, that is, that significant inter-observer variability exists in
the differentiation of these lesions from other polyps.11 A
recent single-centre study has demonstrated a large increase in
the diagnosis of SSLs over a 4-year period from 2009, but also
that retrospective review of right-sided lesions originally diag-
nosed as hyperplastic polyps resulted in re-categorisation to
SSLs in 30–64%.12 It has been suggested that the presence of
features of mucosal prolapse may be one of the most frequent
reasons for misdiagnosis of SSLs.13 Since SSLs appear to possess
greater clinical significance than hyperplastic polyps and may
progress more rapidly to adenocarcinoma than ‘classical’ aden-
omas, accurate diagnosis is essential. In the UK, the introduction
of the National Bowel Cancer Screening Programme (BCSP) has
raised the awareness of all forms of colorectal polyp, including
SSLs. Educational events linked to the BCSP should gradually
improve the future consistency of diagnosis of these lesions
among pathologists involved in the programme. There is some
evidence that achieving a consensus on the diagnostic criteria
for serrated lesions (including hyperplastic polyps and TSAs)
to between reporting pathologists can improve the consistency of
diagnosis of these lesions.14

‘Pure’ SSLs do not show ‘conventional’ dysplasia, that is, dysplas-
ia as is characteristic of ‘classical’ adenomas, although they do
characteristically show ‘dysmaturation’ (box 1). However, dyspla-
sia can develop within them—both low and high grade. The
natural history of SSLs with and without ‘conventional’ dysplasia
is not fully defined. However, it is believed that the development
of ‘conventional’ dysplasia is indicative of a high risk of progres-
sion to CRC and that malignancy may supervene more rapidly
than with ‘classical’ adenomas.5 15 The term ‘mixed polyps’ has
been used to describe SSLs that include an area of ‘conventional’
dysplasia. However, this term may not be ideal as it could be inter-
preted as implying that these lesions develop de novo as a combi-
ation of SSL and ‘conventional’ dysplasia rather than following
the occurrence of ‘conventional’ dysplasia within a pre-existing SSL
that originally developed without ‘conventional’ dysplasia. The
alternative term ‘sessile serrated adenoma’ has been suggested to
describe SSLs with (or sometimes, indeed, without) ‘conventional’
dysplasia. The use of this term is understandable as the areas of
‘conventional’ dysplasia in these lesions frequently possess a ser-
rated morphology, even when it is high grade in nature.15
However, at present, the phrase ‘sessile serrated adenoma’ is used
more commonly in North America than in the UK.

‘Conventional’ dysplasia is recognisable when it occurs in
SSLs using the same criteria for its recognition in ‘classical’
adenomas. However, loss of the DNA mismatch repair enzymes
hMLH-1 and hMSH-2 is commonly seen in ‘conventional’ dysplasia
arising in SSLs, and therefore demonstration of loss of expression
of these proteins using immunohistochemistry may
be useful to confirm the presence of dysplasia occurring in this
setting.16 However, since loss of DNA mismatch repair enzyme
expression occurs in these lesions due to inactivation of the
gene promoter sequence, demonstration of loss of expression
of these proteins in this context does not imply that the patient has
Lynch syndrome, that is, a germline mutation in the correspond-
ing gene (figure 3) (see later).

Traditional serrated adenomas
TSAs are relatively uncommon lesions that occur most fre-
quently in the left colon and are characterised by tubulovillous
architecture, eosinophilic cytoplasm, elongated (‘pencillate’)
nuclei and ectopic crypts, that is, the presence of multiple tiny
crypts extending from the primary crypts (figure 4). The latter


867

Downloaded from http://jcp.bmj.com/ on July 6, 2017 - Published by group.bmj.com
The proportion of a lesion that is required to show the characteristic features of a TSA—in contrast to areas showing the appearances of a ‘classical’ adenoma—in order to make a diagnosis of TSA is not clearly defined. Neoplastic epithelium with a focally eosinophilic appearance may be seen in lesions that otherwise show the features of a ‘classical’ tubulovillous adenoma and without the constellation of features that are

The proportion of a lesion that is required to show the characteristic features of a TSA—in contrast to areas showing the appearances of a ‘classical’ adenoma—in order to make a diagnosis of TSA is not clearly defined. Neoplastic epithelium with a focally eosinophilic appearance may be seen in lesions that otherwise show the features of a ‘classical’ tubulovillous adenoma and without the constellation of features that are
characteristic of TSAs (figure 4). These lesions are best regarded as ‘classical’ adenomas. However, some lesions comprise almost equal proportions of TSA-like and ‘classical adenoma’-like areas, and it is likely that these will be termed TSAs by some and ‘mixed’ TSA and ‘classical’ adenomas by others. Regardless of the precise terminology used in this situation, the key step is to recognise the lesion as a variant of an adenoma and to be able to grade the dysplasia accurately, as these assessments will allow the correct risk stratification.

Endoscopic recognition of serrated lesions
SSLs are often difficult to recognise using conventional endoscopy (figure 5). Presumably this is due to their flat growth pattern and their not uncommon association with mucosal folds. They are also prone to being covered within mucus.18 Endoscopic identification rates for SSLs vary significantly between studies—from 1% to 18% in one study.19 Advanced techniques such as magnifying endoscopy and narrow band imaging may enhance their visualisation.20 21 The location and size of serrated lesions can help the endoscopist to determine whether they are likely to be dealing with an HP, an SSL or a TSA. TSAs are more commonly pedunculated, while some have suggested that they possess a red colouration on endoscopic examination—although this does not seem to be a universally held belief.18

SERRATED POLYPISIS
Serrated polyposis (aka hyperplastic polyposis) is a condition characterised by the presence of multiple serrated polyps within the colorectum. Criteria for the diagnosis of this condition have now been created (box 2).10 The distinct morphological features of these polyps were described by Torkildsen and Snover in 1996, highlighting that the polyps in this syndrome showed important differences from those of sporadic hyperplastic polyps.2 The polyps found in serrated polyposis may be quite variable in histological appearance, even within the same patient. However, the majority show features most in keeping with those of SSLs, with some showing the appearances of ‘classical’ adenomas.2 The fact that the majority of lesions in patients with this condition show the features of SSLs explains why—
prior to the identification of SSLs as a distinct entity—the condition was known as ‘hyperplastic polyposis’.

**SERRATED ADENOCARCINOMA**

It is well established that serrated polyps can progress to CRC (box 3) and the term ‘serrated adenocarcinoma’ has been used to describe these tumours. Just as CRC arising within the classical ‘adenoma-carcinoma’ pathway may be associated with an adjacent residual adenomatous component, serrated polyps are sometimes visible at the edge of CRC arising within the ‘serrated’ pathway. Second, the invasive carcinoma may itself show morphological features that are characteristic of CRC arising in

---

**Figure 4** The histological features of traditional ‘serrated adenomas (TSAs). (a) Low-power view to show filiform architecture. Magnification ×40. (b) Eosinophilic cytoplasm and pencillate nuclei with crypt budding. Magnification ×100. (c) and (d) Crypt budding. Magnification ×200. (e) Crypt budding. Magnification ×400. (f) Eosinophilic cytoplasm and pencillate nuclei. Magnification ×400. (g) A tiny focus of eosinophilic cytoplasm and pencillate nuclei within an otherwise typical ‘classical’ tubulovillous adenoma. Magnification ×200. (h) A focus of crypt budding within an otherwise typical ‘classical’ tubulovillous adenoma. Magnification ×100. All—H&E stain.
the context of the ‘serrated’ pathway. Before the link between serrated polyps and ‘serrated adenocarcinoma’ was established, the features of ‘serrated adenocarcinoma’ were described within cancers that were MSI-H but sporadic in nature, that is, not arising on the basis of Lynch syndrome. It is very likely that many, if not all, of these cancers in fact arise via the ‘serrated’ pathway. It is currently thought that around a third of cancers that arise from the ‘serrated pathway’ show a serrated morphology—therefore, the majority show features that are not distinguishable from cancers arising from the ‘classical’ adenoma-carcinoma sequence. The key histological features of ‘serrated adenocarcinomas’ that distinguish them from ‘conventional’ adenocarcinomas are listed in table 3. Of these appearances, the serrated growth pattern is the most common and the trabecular pattern is the rarest.

The majority of ‘serrated adenocarcinomas’ arise in the distal colon or rectum. These tumours are MSI-S or exhibit MSI-L and are believed to develop from TSAs. A minority arise within the caecum and ascending colon, show MSI-H and are thought to arise from SSLs. There is some evidence that serrated adenocarcinomas possess a worse prognosis than CRC developing along the ‘adenoma-carcinoma’ pathway. In particular, they more commonly show adverse histological factors such as tumour budding. Some will also contain KRAS mutations, and these tumours will be resistant to anti-EGFR therapies in the same way to KRAS-mutant CRC arising from the ‘adenoma-carcinoma’ pathway (see below).

The KRAS gene encodes the KRAS protein (a proto-oncogene), which is a member of the Ras family of proteins that are very important for signalling in normal cells. Mutations within the KRAS gene are commonly found in carcinomas of the pancreas, lung and colorectum and result in KRAS acting as an oncogene. In CRC, the presence of a KRAS mutation is also a predictor of a poor response to EGFR inhibitors such as cetuximab. This is because certain KRAS mutations result in the KRAS protein becoming self-activating and because KRAS is downstream of EGFR in the signal transduction pathway; pharmacological inhibition of EGFR does not then prevent (aberrant) signal transduction via this pathway when KRAS is mutant.

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Detailed appearances</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serrated</td>
<td>Well-differentiated glands in which the epithelium has a serrated appearance</td>
</tr>
<tr>
<td></td>
<td>Eosinophilic cytoplasm—may be intense*</td>
</tr>
<tr>
<td></td>
<td>Vesicular (open chromatin) nuclei with basal location*</td>
</tr>
<tr>
<td></td>
<td>Dirty necrosis focal or absent</td>
</tr>
<tr>
<td></td>
<td>May possess small areas of mucinisation differentiation</td>
</tr>
<tr>
<td>Mucinous</td>
<td>The neoplastic cells are present usually as (poorly differentiated) cords of cells floating within the mucus pools</td>
</tr>
<tr>
<td></td>
<td>‘Serrated cytology’ retained</td>
</tr>
<tr>
<td></td>
<td>Areas with a ‘serrated morphology’ can form up to 50% of the tumour</td>
</tr>
<tr>
<td>Trabecular</td>
<td>Poorly differentiated clusters and cords of neoplastic epithelial cells</td>
</tr>
<tr>
<td></td>
<td>‘Serrated cytology’ maintained</td>
</tr>
<tr>
<td></td>
<td>Lymphatic invasion common</td>
</tr>
<tr>
<td></td>
<td>This pattern may be seen at the advancing edge of serrated adenocarcinomas that are otherwise one of the other two subtypes</td>
</tr>
</tbody>
</table>

*‘Serrated cytology’ refers to the combination of these nuclear and cytoplasmic features.
The BRAF gene (another proto-oncogene) encodes a protein called B-Raf, which is a member of the Raf kinase family of phosphorylating enzymes that are involved in the control of cell division and differentiation. Acquired BRAF mutations have been identified in many human cancers, including malignant melanoma and carcinomas of the lung and colorectum. These mutations result in BRAF acting as an oncogene. Over 30 mutations have been recognised in the BRAF gene, of which the V600E mutation is the most common (90% of BRAF mutations). The V600E mutation is a single-nucleotide substitution at codon 600 of the gene, leading to an amino acid change from valine (V) to glutamate (E) at this position. CRCs showing both loss of the hMLH-1 protein and the presence of the V600E mutation have lost hMLH-1 expression due to inactivation of the hMLH-1 encoding gene rather than due to an inherited mutation in the corresponding gene. Methylation may be present at either a low (CIMP-L) or high (CIMP-H) level across the genome. Mutations in the KRAS gene may also occur, and the resulting CRCs are MSS and either CIMP-negative or CIMP-L.

Familial adenomatous polyposis (FAP) is associated with a germline mutation in the APC gene, and the resulting CRC are CIMP-negative and MSS. Lynch syndrome is associated with a germline mutation in one of the DNA mismatch repair enzyme-encoding genes, and the resulting CRC are CIMP-negative and show MSI (the latter is associated with resistance to 5-fluorouracil chemotherapy).

SSLs are associated with early BRAF mutations followed in some cases by loss of hMLH-1 expression due to hypermethylation of the promoter sequence leading to inactivation of the encoding gene, rather than due to a mutation. One study of 148 colorectal polyps found that 90% of SSLs contain the BRAF V600E mutation compared with 29% of (microvesicular) hyperplastic polyps, 36% of TSAs and 5% of ‘classical’ adenomas. The resulting CRC contain BRAF mutations, are CIMP-H and exhibit MSI. SSLs in which hMLH-1 expression is not lost may alternatively show p16 and MGMT loss. The resulting CRC again contain BRAF mutations and exhibit CIMP-H but are MSS.

The p16 gene is a tumour suppressor gene encoding a protein (cyclin-dependent kinase inhibitor 2A) that is involved in cell cycle control and that may be mutated in several different cancers. The MGMT gene encodes the MGMT protein (methylated DNA protein cytosome methyltransferase) that is involved in DNA repair and that can be inactivated via hypermethylation of its promoter sequence.

Microsatellites are short, non-coding regions of DNA that are scattered throughout the genome. They can act as markers of imperfect DNA replication since when this occurs individual microsatellites are present at differing length within different cells. This phenomenon is termed ‘microsatellite instability’ (MSI). MSI can be present only in some microsatellites (MSI-low or MSI-L) or within many (MSI-high or MSI-H). The presence of MSI-H is commonly associated with defective DNA mismatch repair (ie, the failure of the normal process of correction of imperfections in DNA replication) and is characteristic of Lynch syndrome and in certain CRCs that arise from the serrated pathway. Lesions that show no evidence of MSI are termed ‘microsatellite stable’ (MSS).

The CIMP is a state in which extensive methylation of the promoter sequences of genes—including those encoding certain DNA mismatch repair enzymes—occurs. CpG islands are pairs of cytosine and guanine nucleotides that are present mainly within the promoter regions of genes such as the DNA mismatch repair enzyme-encoding gene hMLH-1. When methylation (a physiological process important in the regulation of gene activity) of these CpG islands occurs, this results in inactivation of the corresponding gene. Methylation may be present at either a low (CIMP-L) or high (CIMP-H) level across the genome.

The Wnt signalling pathways are important cascades of proteins that are involved in signal transduction and control of cellular growth and differentiation. Genes encoding proteins within this pathway can act as oncogenes when their regulation becomes abnormal.

Several different molecular pathways to CRC exist (table 5). The classical Vogelstein ‘adenoma-carcinoma’ model has been established for many years and involves what is believed to be a stepwise accumulation in mutations within, for example, APC (adenomatous polyposis coli; commonly mutated early in CRC), p53 (an important tumour suppressor gene involved in halting cellular proliferation in the presence of DNA damage and promoting apoptosis if this damage cannot be repaired) and SMAD4 genes (one of a family of genes encoding proteins involved in signal transduction within the TGF-β pathway).

Management of Serrated Lesions

Whether or not serrated polyps are identified within the context of the BCSP, the most appropriate management of affected

### Table 4: The genes most commonly involved (through inactivation, loss or mutation) during the molecular pathways from normal colorectal mucosa to CRC

<table>
<thead>
<tr>
<th>BRAF</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRAS</td>
<td>hMLH-1</td>
</tr>
<tr>
<td>p16</td>
<td>p53</td>
</tr>
<tr>
<td>MGMT</td>
<td>SMAD4</td>
</tr>
</tbody>
</table>

*Familial CRC proceeds down a very similar pathway to the adenoma-carcinoma sequence; in familial adenomatous polyposis a germline mutation in the APC gene is present while in Lynch syndrome a germline mutation in one of the DNA mismatch repair enzymes is present. In both conditions, the second allele of the corresponding gene is then lost or inactivated through mutation.

### Table 5: Molecular classification of colorectal cancer

<table>
<thead>
<tr>
<th>Type</th>
<th>CIMP</th>
<th>MSI</th>
<th>BRAF</th>
<th>KRAS</th>
<th>Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>High</td>
<td>High</td>
<td>Mutation</td>
<td>WT</td>
<td>Serrated</td>
</tr>
<tr>
<td>2</td>
<td>High</td>
<td>Low or stable</td>
<td>Mutation</td>
<td>WT</td>
<td>Serrated</td>
</tr>
<tr>
<td>3</td>
<td>Low</td>
<td>Low or stable</td>
<td>WT</td>
<td>Mutation</td>
<td>Serrated or adenoma-carcinoma</td>
</tr>
<tr>
<td>4</td>
<td>Neg</td>
<td>Stable</td>
<td>WT</td>
<td>WT</td>
<td>Adenoma-carcinoma</td>
</tr>
<tr>
<td>5</td>
<td>Neg</td>
<td>High</td>
<td>WT</td>
<td>WT</td>
<td>Lynch syndrome</td>
</tr>
</tbody>
</table>

Note that CIMP-H status may or may not result in MSI depending on whether hMLH-1 is one of the genes inactivated as a result of hypermethylation of its promoter sequence.

CIMP: CpG island methylator phenotype; MSI, microsatellite instability; WT, wild type (ie, not mutant).
The development of UK guidelines for the CRC may be more rapid than the classical ‘careful scrutiny’. It is likely that guidance will advocate complete excision of SSLs, as well as clinical follow-up, which will be initiated at a site visit from 2–6 months if a large proximal SSL or multiple SSLs are identified, the use of advanced endoscopic techniques should be considered as a means of increasing the detection rate of serrated polyposis SSL, sessile serrated lesion.

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES


Box 4  A suggested colonoscopic surveillance protocol for SSLs

The numbers of SSLs and ‘classical’ adenomas should be additive. For example, the finding of two classical adenomas <10 mm and one SSL <10 mm should lead to 3-yearly surveillance. Distal small hyperplastic polyps are not associated with an increased risk of colorectal cancer and surveillance should not be increased in frequency because of these lesions unless >20 are present.

If the pathologist is unable to distinguish between a hyperplastic polyp and an SSL for technical reasons (eg, tiny biopsy or tangential cutting), then all proximal serrated polyp should be considered to represent SSLs.

Patients with serrated polyposis should undergo 2-yearly surveillance after all lesions >5 mm have been resected.

Patients undergoing piecemeal resection of an SSL should undergo a site check at 2–6 months.

If a large proximal SSL or multiple SSLs are identified, the use of advanced endoscopic techniques should be considered as a means of increasing the detection rate of serrated polyposis SSL, sessile serrated lesion.

Key messages

- ‘Serrated neoplasia’ refers to a range of colorectal lesions with varying degrees of malignant risk, together with distinct forms of adenocarcinoma.
- Bowel Cancer Screening Programmes have highlighted to histopathologists the importance of recognizing and understanding the biological significance of the spectrum of serrated lesions.
- The optimal terminology, minimum diagnostic criteria and most appropriate management strategies for some serrated lesions (especially the sessile serrated lesion) are still in evolution.

FUTURE ADVANCES

Further elucidation of the molecular links between the entire spectrum of serrated lesions and CRC will help to inform the guidelines for patient management and follow-up. In particular, a better understanding of the speed of progression along the ‘serrated pathway’ to CRC may allow enhanced risk stratification for patients in whom these lesions are identified. The similarities between microvesicular hyperplastic polyps and SSLs require further detailed study, and this could lead to a change to the paradigm that sporadically occurring hyperplastic polyps possess no link with the future development of CRC.


